por
John R. Fischer, Senior Reporter | December 21, 2021
The deal is expected to be immediately accretive to Oracle's earnings in the first full fiscal year after the transaction is completed. The transaction is subject to certain regulatory approvals and closing conditions. Cerner stockholders must agree to sell a majority of Cerner's outstanding shares as part of Oracle's offer.
Oracle and Cerner did not respond to HCB News for comment.
Back to HCB News